The use of zoledronic acid, a novel, highly potent bisphosphonate, for the treatment of hypercalcemia of malignancy

Oncologist

Volumn 7, Issue 6, 2002, Pages 481-491

  Major, Pierre ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b JURAVINSKI CANCER CENTRE   (Canada)

Author keywords

Bisphosphonate; Bone metastases; Hypercalcemia of malignancy; Pamidronate disodium; Zoledronic acid

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; CLODRONIC ACID; ETIDRONIC ACID; IBANDRONIC ACID; PAMIDRONIC ACID; ZOLEDRONIC ACID;

BONE METASTASIS; CALCIUM BLOOD LEVEL; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERANCE; ESOPHAGITIS; FEVER; FLU LIKE SYNDROME; GASTROINTESTINAL TOXICITY; HUMAN; HYPERCALCEMIA; HYPOPHOSPHATEMIA; KIDNEY FAILURE; META ANALYSIS; NAUSEA; OSTEOLYSIS; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; THROMBOCYTOPENIA;

ANTI-INFLAMMATORY AGENTS; BONE RESORPTION; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYPERCALCEMIA; IMIDAZOLES; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 0036913512     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.7-6-481     Document Type: Review

References (69)

1. Mundy GR, Ibbotson KJ, D'Souza SM et al. The hypercalcemia of cancer: Clinical implications and pathogenic mechanisms. N Engl J Med 1984;310:1718-1727.
2. Vassilopoulou-Sellin R, Newman BM, Taylor SH et al. Incidence of hypercalcemia in patients with malignancy referred to a comprehensive cancer center. Cancer 1993;71:1309-1312.
3. Watters J, Gerrand G, Dodwell D. The management of malignant hypercalcaemia. Drugs 1996;52:837-848.
4. CancerNet™. Hypercalcemia (PDQ®) Supportive Care - Health Professionals. Available at: http://www.cancer.gov/cancer_ information/doc_pdq.aspx?version=provider&viewid=22c0dfe b-f468-4341-8519-27b71bb4686d. Accessed September 10, 2002.
5. Stewart AF, Horst R, Deftos LJ et al. Biochemical evaluation of patients with cancer-associated hypercalcemia: Evidence for humoral and nonhumoral groups. N Engl J Med 1980;303:1377-1383.
6. Grill V, Martin TJ. Hypercalcemia. In: Rubens RD, Mundy GR, eds. Cancer and the Skeleton. London: Martin Dunitz Ltd., 2000:75-89.
7. Berenson JR, Lichtenstein A, Porter L et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med 1996;334:488-493.
8. Mundy GR. Myeloma bone disease. Eur J Cancer 1998;34:246-251.
9. Mundy GR. Metastatic bone disease. In: Bone Remodeling and Its Disorders, Second Edition. London: Martin Duntiz Ltd., 1999:123-146.
10. Ralston SH, Fogelman I, Gardiner MD et al. Relative contribution of humoral and metastatic factors to the pathogenesis of hypercalcaemia in malignancy. Br Med J (Clin Res Ed) 1984;288:1405-1408.
11. Roodman GD. Biology of osteoclast activation in cancer. J Clin Oncol 2001;19:3562-3571.
12. Data on file. ZOMETA Product Monograph. East Hanover, NJ: Novartis Pharmaceuticals Corporation, 2001.
13. Kong YY, Boyle WJ, Penninger JM. Osteoprotegerin ligand: A regulator of immune responses and bone physiology. Immunol Today 2000;21:495-502.
14. Kong YY, Penninger JM. Molecular control of bone remodeling and osteoporosis. Exp Gerontol 2000;35:947-956.
15. Pearse RN, Sordillo EM, Yaccoby S et al. Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci USA 2001;98:11581-11586.
16. Major P, Lortholary A, Hon J et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: A pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 2001;19:558-567.
17. Firkin F, Seymour JF, Watson AM et al, Parathyroid hormone-related protein in hypercalcaemia associated with haematological malignancy. Br J Haematol 1996;94:486-492.
18. Ralston SH. Pathogenesis and management of cancer-associated hypercalcaemia. In: Rubens RD, Fogelman I, eds. Bone Metastases: Diagnosis and Treatment. London: Springer-Verlag, 1991:149-158.
19. Benford HL, Frith JC, Auriola S et al. Famesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: Biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs. Mol Pharmacol 1999;56:131-140.
20. Russell RGG, Rogers MJ. Bisphosphonates: From the laboratory to the clinic and back again. Bone 1999;25:97-106.
21. Luckman SP, Hughes DE, Coxon FP et al. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 1998;13:581-589.
22. Bonde M, Qvist P, Fledelius C et al. Immunoassay for quantifying type I collagen degradation products in urine evaluated. Clin Chem 1994;40:2022-2025.
23. Hanson DA, Weis MA, Bollen AM et al. A specific immunoassay for monitoring human bone resorption: Quantitation of type I collagen cross-linked N-telopeptides in urine. J Bone Miner Res 1992;7:1251-1258.
24. Seibel MJ, Robins SP, Bilezikian JP. Urinary pyridinium crosslinks of collagen: Specific markers of bone resorption in metabolic bone disease. Trends Endocfinol Metab 1992;3:263-270.
25. Woitge HW, Pecherstorfer M, Li Y et al. Novel serum markers of bone resorption: Clinical assessment and comparison with established urinary indices. J Bone Miner Res 1999;14:792-801.
26. Walls J, Assiri A, Howell A et al. Measurement of urinary collagen cross-links indicate response to therapy in patients with breast cancer and bone metastases. Br J Cancer 1999;80:1265-1270.
27. Rogers MJ, Frith JC, Luckman SP et al. Molecular mechanisms of action of bisphosphonates. Bone 1999;24(5 suppl):73S-79S.
28. Russell RG, Rogers MJ, Frith JC et al. The pharmacology of bisphosphonates and new insights into their mechanisms of action. J Bone Miner Res 1999;14(suppl 2):53-65.
29. Luckman SP, Coxon FP, Ebetino FH et al. Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: Evidence from structure-activity relationships in J774 macrophages. J Bone Miner Res 1998;13:1668-1678.
30. Oliff A. Famesyltransferase inhibitors: Targeting the molecular basis of cancer. Biochim Biophys Acta 1999;1423:C19-C30.
31. Zhang FL, Casey PJ. Protein prenylation: Molecular mechanisms and functional consequences, Annu Rev Biochem 1996;65:241-269.
32. Benford HL, Helfrich MH, Sebti S et al. Inhibition of protein geranylgeranylation by bisphosphonates and GGTI298 causes activation of caspase 3-like proteases in osteoclasts [abstract]. Calcif Tissue Int 1999;64(suppl 1):S45.
33. McCloskey EV, MacLennan IC, Drayson MT et al. A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma, MRC Working Party on Leukaemia in Adults. Br J Haematol 1998;100:317-325.
34. Paterson AH, Powles TJ, Kanis JA et al. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 1993;11:59-65.
35. Flores JF, Rude RK, Chapman RA et al. Evaluation of a 24-hour infusion of etidronate disodium for the treatment of hypercalcemia of malignancy. Cancer 1994;73:2527-2534.
36. Meunier PJ, Chapuy MC, Delmas P et al. Intravenous disodium etidronate therapy in Paget's disease of bone and hypercalcemia of malignancy. Effects on biochemical parameters and bone histomorphometry. Am J Med 1987;82:71-78.
37. Major PP, Lipton A, Berenson J et al. Oral bisphosphonates: A review of clinical use in patients with bone metastases. Cancer 2000;88:6-14.
38. Body JJ, Bartl R, Burckhardt P et al. Current use of bisphosphonates in oncology. International Bone and Cancer Study Group. J Clin Oncol 1998;16:3890-3899.
39. Body JJ. Dosing regimens and main adverse events of bisphosphonates. Semin Oncol 2001;28(suppl 11):49-53.
40. Zojer N, Keck AV, Pecherstorfer M. Comparative tolerability of drug therapies for hypercalcaemia of malignancy. Drug Saf 1999;21:389-406.
41. O'Rourke NP, McCloskey EV, Vasikaran S et al. Effective treatment of malignant hypercalcaemia with a single intravenous infusion of clodronate. Br J Cancer 1993;67:560-563.
42. Purohit OP, Radstone CR, Anthony C et al. A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy. Br J Cancer 1995;72:1289-1293.
43. Fatemi S, Singer FR, Rude RK. Effect of salmon calcitonin and etidronate on hypercalcemia of malignancy. Calcif Tissue Int 1992;50:107-109.
44. Ralston SH, Gallacher SJ, Patel U et al. Comparison of three intravenous bisphosphonates in cancer-associated hypercalcemia. Lancet 1989;2:1180-1182.
45. Warrell Jr RP, Murphy WK, Schulman P et al. A randomized double-blind study of gallium nitrate compared with etidronate for acute control of cancer-related hypercalcemia. J Clin Oncol 1991;9:1467-1475.
46. Bounameaux HM, Schifferli J, Montani JP et al. Renal failure associated with intravenous diphosphonates. Lancet 1983;1:471.
47. Rizzoli R, Buchs B, Bonjour JP. Effect of a single infusion of alendronate in malignant hypercalcaemia: Dose dependency and comparison with clodronate. Int J Cancer 1992;50:706-712.
48. Nussbaum SR, Warrell Jr RP, Rude R et al. Dose-response study of alendronate sodium for the treatment of cancer-associated hypercalcemia. J Clin Oncol 1993;11:1618-1623.
49. Ralston SH, Thiébaud D, Herrmann Z et al. Dose-response study of ibandronate in the treatment of cancer-associated hypercalcaemia. Br J Cancer 1997;75:295-300.
50. Pecherstorfer M, Herrmann Z, Body JJ et al. Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy. J Clin Oncol 1996;14:268-276.
51. Thiébaud D, Jaeger P, Jacquet AF et al. A single-day treatment of tumor-induced hypercalcemia by intravenous amino-hydroxypropylidene bisphosphonate. J Bone Miner Res 1986;1:555-562.
52. Thiébaud D, Jaeger P, Jacquet AF et al. Dose-response in the treatment of hypercalcemia of malignancy by a single infusion of the bisphosphonate AHPrBP. J Clin Oncol 1988;6:762-768.
53. Gucalp R, Ritch P, Wiernik PH et al. Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia. J Clin Oncol 1992;10:134-142.
54. Body JJ, Dumon JC. Treatment of tumour-induced hypercalcaemia with the bisphosphonate pamidronate: Dose-response relationship and influence of tumour type. Ann Oncol 1994;5:359-363.
55. Nussbaum SR, Younger J, Vandepol CJ et al. Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: Comparison of 30-, 60-, and 90-mg dosages. Am J Med 1993;95:297-304.
56. Vinholes J, Guo CY, Purohit OP et al. Evaluation of new bone resorption markers in a randomized comparison of pamidronate or clodronate for hypercalcemia of malignancy. J Clin Oncol 1997;15:131-138.
57. Dodwell DJ, Howell A, Morton AR et al. Infusion rate and pharmacokinetics of intravenous pamidronate in the treatment of tumour-induced hypercalcaemia. Postgrad Med J 1992;68:434-439.
58. Green JR, Müller K, Jaeggi KA. Preclinical pharmacology of CGP 42′446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res 1994;9:745-751.
59. Body JJ, Lortholary A, Romieu G et al. A dose-finding study of zoledronate in hypercalcemic cancer patients. J Bone Miner Res 1999;14:1557-1561.
60. Berenson JR, Vescio RA, Rosen LS et al. A phase I doseranging trial of monthly infusions of zoledronic acid for the treatment of osteolytic bone metastases. Clin Cancer Res 2001;7:478-485.
61. Berenson JR, Vescio R, Henick K et al. A phase I, open label, dose ranging trial of intravenous bolus zoledronic acid, a novel bisphosphonate, in cancer patients with metastatic bone disease. Cancer 2001;91:144-154.
62. Thiébaud D, Jaeger P, Burckhardt P. Response to retreatment of malignant hypercalcemia with the bisphosphonate AHPrBP (APD): Respective role of kidney and bone. J Bone Miner Res 1990;5:221-226.
63. Ostenstad B, Andersen OK. Disodium pamidronate versus mithramycin in the management of tumour-associated hypercalcemia. Acta Oncol 1992;31:861-864.
64. Gucalp R, Theriault R, Gill I et al. Treatment of cancer-associated hypercalcemia. Double-blind comparison of rapid and slow intravenous infusion regimens of pamidronate disodium and saline alone. Arch Intern Med 1994;154:1935-1944.
65. Diener KM. Bisphosphonates for controlling pain from metastatic bone disease. Am J Health Syst Pharm 1996;53:1917-1927.
66. Green JR, Seltenmeyer Y, Jaeggi KA et al. Renal tolerability profile of novel, potent bisphosphonates in two short-term rat models. Pharmacol Toxicol 1997;80:225-230.
67. Berenson JR, Rosen LS, Howell A et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases: A double-blind, randomized dose-response study [published erratum appears in Cancer 2001;91:1956]. Cancer 2001;91:1191-1200.
68. Saad F, Gleason DM, Murray R et al. Zoledronic acid reduces skeletal complications in patients with hormone-refractory prostate carcinoma metastatic to bone: A randomized, placebo-controlled trial. J Natl Cancer Inst 2002;94:1458-1468.
69. Body JJ. Clinical research update: Zoledronate. Cancer 1997;80(suppl 8):1699-1701.